Archives | Biotech Investment Paradigm

Archives

The Last 30 Posts

Will the FDA Remove Zevalin’s Bioscan? - November 18, 2011 - 2 comments
DUSA Pharmaceuticals Shares Tumble After Earnings Release: Low Growth Ahead? - November 11, 2011 - 0 comments
Inhibitex Announces Positive Topline Data in HCV Program - November 8, 2011 - 0 comments
Seattle Genetics Updates Investors on Adcetris Launch and Label Expansion - November 6, 2011 - 0 comments
LPath Investors Have iSONEP Trial Results in Sight - November 1, 2011 - 0 comments
Raptor Pharmaeuticals Provides Update on Lead Candidate – RP103 - October 27, 2011 - 0 comments
Sangamo Provides Guidance on HIV/AIDS Program - October 26, 2011 - 0 comments
Exelixis Reports Positive Data in EXAM Trial of Cabozantinib in Medullary Thyroid Cancer - October 25, 2011 - 1 comments
Roche Acquisition of Anadys Draws Attention to Growing Hepatitis C Arena - October 20, 2011 - 0 comments
Exelixis to Release Topline Data from EXAM This Quarter - October 11, 2011 - 0 comments
Sangamo Kills Program in Diabetic Neuropathy Following Failed Phase 2b Trial - October 3, 2011 - 0 comments
Strong Potential for Future Success in Sangamo’s Early HIV Treatment Data - September 27, 2011 - 0 comments
Recent Analyst Activity - September 24, 2011 - 0 comments
What Does the Market Think are Peginesatide’s Approval Odds? - September 23, 2011 - 0 comments
Pharmasset’s Potential to Shift the Hepatitis C Treatment Paradigm - September 21, 2011 - 2 comments
Recent Analyst Activity - September 9, 2011 - 0 comments
Valuation of Vivus’ Avanafil: A Good Drug a Decade Too Late - September 4, 2011 - 0 comments
Why Amarin’s IP Situation is Overblown: Valuation of the Worst Case Scenario - August 26, 2011 - 7 comments
Spectrum Pharmaceuticals Continues to Over-Promise and Under-Deliver - August 23, 2011 - 0 comments
Seattle Genetics’ Adcetris Secures Approval with a Favorable Label and a Hefty Pricetag - August 22, 2011 - 0 comments
Company Updates: Seattle Genetics and Vivus - August 18, 2011 - 0 comments
Company Updates in Brief: Affymax, Corcept, Optimer, Protalix - August 16, 2011 - 0 comments
Fighting Resistance: Trius’ Torezolid for Acute Bacterial Infections - August 14, 2011 - 0 comments
Recent Analyst Activity - August 13, 2011 - 0 comments
Why Vertex is a Buy: Second Quarter Results - July 31, 2011 - 1 comments
Recent Analyst Activity - July 30, 2011 - 0 comments
Sangamo BioSciences Reports Second Quarter Results - July 28, 2011 - 0 comments
FDA Accepts Affymax’ NDA for Peginesatide in Chronic Renal Failure - July 27, 2011 - 0 comments
Biotech Valuation Part 2: Market Size and rNPV applied to Prolor Biotech - July 21, 2011 - 0 comments
FDA Advisory Committee Votes Unanimously to Recommend Accelerated Approval of Seattle Genetics’ Adcetris - July 18, 2011 - 0 comments

Categories

Monthly Archives